Mitochondrial DNA variants correlate with symptoms in myalgic encephalomyelitis/chronic fatigue syndrome.
Billing-Ross, Paul, Germain, Arnaud, Ye, Kaixiong et al. · Journal of translational medicine · 2016 · DOI
Quick Summary
This study examined whether differences in mitochondrial DNA (the genetic instructions inside the energy-producing parts of our cells) are linked to ME/CFS symptoms. Researchers compared DNA from 193 ME/CFS patients and 196 healthy people and found that while certain mitochondrial DNA patterns were associated with specific symptoms like neurological problems, pain, and digestive issues, they were not linked to whether someone actually develops ME/CFS. This suggests mitochondrial DNA variations may influence how severe certain symptoms are, rather than causing the disease itself.
Why It Matters
Understanding which mitochondrial DNA variants correlate with specific ME/CFS symptoms could help clinicians predict symptom patterns and tailor treatment approaches for individual patients. This research supports the mitochondrial dysfunction hypothesis in ME/CFS while suggesting that mitochondrial genetics may be more relevant to symptom manifestation than disease causation, potentially opening new avenues for symptom-specific interventions.
Observed Findings
No ME/CFS participants carried known disease-causing mitochondrial mutations.
Haplogroups J, U, and H showed significant associations with specific ME/CFS symptoms and symptom severity.
Eight specific mtDNA SNPs were significantly associated with individual symptoms, symptom clusters, or symptom severity in ME/CFS cases.
Heteroplasmy (the presence of multiple mtDNA variants within one person) was low in all study subjects.
No statistically significant association was found between mtDNA variants and ME/CFS case versus healthy control status overall.
Inferred Conclusions
Mitochondrial genetic variation in ME/CFS patients is associated with symptom phenotype and severity rather than disease susceptibility itself.
Individuals carrying certain haplogroups or SNPs may be predisposed to exhibit particular neurological, inflammatory, and gastrointestinal symptoms if they develop ME/CFS.
Mitochondrial DNA sequences do not appear to be a primary determinant of ME/CFS onset but may modify the clinical presentation of the disease.
Remaining Questions
Do these mtDNA variants actually impair mitochondrial function, or is the association merely correlational?
Why do specific mtDNA haplogroups correlate with certain symptoms rather than others—what is the underlying biological mechanism?
What This Study Does Not Prove
This study does not prove that mitochondrial DNA variants cause ME/CFS or are necessary for disease development, since no difference in mtDNA between patients and controls was found. It also does not establish whether the observed correlations between mtDNA variants and symptoms are mechanistically causal or merely associated, nor does it clarify whether these variants affect mitochondrial function. The cross-sectional design prevents determination of whether mtDNA variants influence symptom severity or vice versa.